Enhancing non-viral gene editing, processing & expansion of T & NK cells

Cell & Gene Therapy Insights 2023; 9(1), 25–39

DOI: 10.18609/cgti.2023.004

Published: 6 February 2023
Innovator Insight

The cell therapy manufacturing process is extremely labor-intensive with a high degree of complexity, regardless of the cell type in use. One key focus area in the field includes developing closed, automated manufacturing processes to help reduce costs and increase the speed of getting treatments to patients. Cell and gene therapy workflows involve cell collection, isolation, activation, and engineering of cells followed by expansion and concentration, and then either cryopreservation or infusion. To better serve the cell therapy industry, Thermo Fisher Scientific has created flexible, modular systems that can be easily adapted into existing workflows. This article will highlight two recently introduced Thermo Fisher instruments: the Gibco™ CTS™ Rotea™ Counterflow Centrifugation System and the Gibco™ CTS™ Xenon™ Electroporation System.